Mutation burden and other molecular markers of prognosis in colorectal cancer treated with curative intent: results from the QUASAR 2 clinical trial and an Australian community-based series (Lancet Gastroenterology & Hepatology, 2018)

(untitled) - Domingo, E; Camps, C; Kaisaki, P; Parsons, M; Mouradov, D; Pentony, M; Makino, S; Palmieri, M; Ward, R; Hawkins, N; Gibbs, P; Askautrud, H; et al.